People · Operator
Named in public records as an officer, director or promoter · active 2013–2022 · Pharmaceuticals, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Holding Co LLC | — | Pharmaceuticals | Series D+ | $130.0M | $3.9B | 2021 |
| DTx Pharma, Inc. | — | Pharmaceuticals | Series D+ | $113.4M | $2.9B | 2021 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2018 |
| Matchpoint Therapeutics Inc. | — | Pharmaceuticals | Series C | $42.0M | $672.3M | 2022 |
| Watchwith, Inc. | — | Other Technology | Series A | $11.9M | $146.3M | 2013 |
Daniel Becker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Becker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| Michael Lee | 1 | 15 |
| Andrew Adams | 1 | 13 |
| Bruce Booth | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Simeon George | 1 | 8 |
| Andre Turenne | 1 | 7 |
| Derek DiRocco | 1 | 7 |
| Alan Colowick | 1 | 7 |
| Jason Hafler | 1 | 6 |
| MATTHEW HAMMOND | 1 | 5 |
| MICHAEL DYBBS | 1 | 5 |
| Lewis J. Shuster | 1 | 4 |
| Nassim Usman | 1 | 4 |
| Jeffrey Friedman | 1 | 4 |
| John Josey | 1 | 3 |
| Michael Gladstone | 1 | 3 |
| Peter Thompson, M.D. | 1 | 2 |
| Simeon J. George, M.D. | 1 | 2 |
| JULIE PAPANEK GRANT | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.